US Edition
Juvenescence secures $76m funding to advance therapeutic pipeline
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Juvenescence secures $76m funding to advance therapeutic pipeline
The funding will enable the company to deliver critical clinical readouts for its core medicine pipeline. Investor M42 spearheaded the funding round, with continued support from current investors. The post Juvenescence secures $76m funding to advance therapeutic pipeline appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage